key: cord-0020449-r37y4vza
authors: Yong, Ho Min; Park, Sung-Jo; Jeon, Seong Ran; Park, Heesu; Kim, Hyun Gun; Lee, Tae Hee; Park, Junseok; Kim, Jin-Oh; Lee, Joon Seong; Ko, Bong Min; Goong, Hyeon Jeong; Park, Suyeon
title: Endoscopy within 7 days after detecting high calprotectin levels can be useful for therapeutic decision-making in ulcerative colitis
date: 2021-08-27
journal: Medicine (Baltimore)
DOI: 10.1097/md.0000000000027065
sha: 0867d1d3de47eb20442703a8241e61b53e6a54f8
doc_id: 20449
cord_uid: r37y4vza

The aim of this study was to assess the appropriate time interval to identify the association between the fecal calprotectin (FC) test and endoscopic activity, and to evaluate whether the time interval affects the therapeutic plan adjustment in patients with ulcerative colitis (UC). This study included 103 patients who underwent FC tests and endoscopic examinations within the past three months. The FC test results classified cases into three groups as follows: moderate to severe (>200, >250, or >300 μg/g), mild (100–200, 100–250, or 100–300 μg/g), and inactive (<100 μg/g) activity. The Mayo endoscopic subscore was used to determine endoscopic activity. Therapeutic plan adjustment included the addition or increased dosage of anti-inflammatory drugs, steroids, immunomodulators, and biologics. Using the cutoff value for FC of 200 μg/g, the appropriate time interval for dividing the association and non-association between Mayo endoscopic subscore and FC was 7 days (sensitivity, 74.4%; specificity, 50.0%; area under the curve [AUC], 0.6032). When using FC 250 or 300 μg/g, the appropriate time interval was 5.5 days, with a sensitivity of 71.7% and specificity of 49.1 (AUC 0.5862) in FC 250 μg/g, a sensitivity of 69.6%, and a specificity of 47.4 (AUC 0.5549) for FC 300 μg/g. Therapeutic plans changed in 29.1% of patients. In patients with shorter intervals (≤7 days) between the FC test and endoscopy, significant therapeutic plan adjustments were observed in patients with UC (36.5% vs. 17.5%, P = .047). Although the need for endoscopy within 7 days after detecting high FC (≥ 200 μg/g) was not statistically supported, endoscopy within a shorter interval (≤7 days) in UC patients with high FC can help determine the therapeutic plan.

Ulcerative colitis (UC) is a chronic intestinal disease characterized by recurrence and repetition of exacerbations of bowel inflammation. [1, 2] In Asia, its incidence and prevalence are increasing. [3, 4] Traditionally, the therapeutic goal for UC has been to maintain clinical remission by controlling symptoms. Recently, the therapeutic target has been shifted to a more objective parameter, such as mucosal healing, to be associated with continuous remission and reduction of hospitalization or operation for UC. [5] [6] [7] Although the role of endoscopy is essential for mucosal inflammation assessment, it is uncomfortable, invasive, and expensive, and may induce major complications such as colon perforation.

On the other hand, fecal calprotectin (FC) analysis is deemed to be more easily accessible and noninvasive than endoscopy. [8] FC, which reflects neutrophil migration into the gut lumen, has been used as a surrogate marker to predict endoscopic activity in UC patients. [9] [10] [11] In addition, a recent meta-analysis showed that FC has high sensitivity (75%), specificity (77%), and positive likelihood ratio (3.45) in predicting UC relapse in adult. [12] Nevertheless, endoscopy is still considered the gold standard for the evaluation of intestinal mucosal inflammation because changes in therapeutic options are not recommended based only on FC measurement in symptomatic UC patients. [13, 14] The timing of FC testing should be at the same time as the endoscopy to more accurately determine the association between the FC test and endoscopic disease activity, and vice versa. In practice, however, both tests cannot be easily performed simultaneously. Although the role of FC in predicting recurrence in UC patients and the relationship between high levels of FC and high levels of intestinal inflammation have been almost established, to the best of our knowledge no study has examined the appropriate time interval to confirm the association between the FC measurement and endoscopic disease activity in patients with UC. Therefore, the aim of this study was to assess the appropriate time interval to confirm the association between the FC test and endoscopic activity, and to evaluate whether the time interval affects the therapeutic plan adjustment in patients with UC.

This study was retrospectively conducted on 103 cases (79 patients) with FC tests and endoscopic examinations performed within three months of each other, between February 2015 and September 2019 at the Soonchunhyang University Hospital. Patients with previous surgical bowel operation, indeterminate or nonspecific colitis, liver disease, combined gastrointestinal tract infection, malignancy, hematologic disorder, pulmonary or heart disease, autoimmune disease, or kidney disease were excluded. This study was approved by our institutional review board (SCHUH 2019-12-003). Patient consent to participate was waived in accordance with the institutional review board. The study protocol followed the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the institution's human research committee.

EliA TM Calprotectin 2 (Phadia AB, Uppsala, Sweden) kits were used to measure FC levels. Fecal samples were collected at home or in a hospital. When collected at home, patients were instructed to refrigerate their fecal samples (2-8°C). The fecal samples were stored in aliquots at À20°C or below until analysis using the fluorescence immunoassay method per manufacturer's instructions was performed. The EliA Calprotectin 2 kit measures FC levels in the range of 3.8 -≥ 6,000 mg/g. As stated by the manufacturer, the cutoff level of FC, representing a positive value, was ≥ 50 mg/g. Based on previous studies. [13, 15] the FC test results classified cases as follows: moderate to severe (>200 mg/g, >250 mg/g, or >300 mg/g), mild (100-200 mg/g, 100-250 mg/g, or 100-300 mg/g), and inactive (<100 mg/g) activity. FC cutoff values of 200 mg/g, 250 mg/g and 300 mg/g were denoted as FC1, FC2, and FC3, respectively.

The UC clinical phenotype was classified according to the Montreal classification. [16] The Mayo score was used to evaluate the activity of UC disease. The Mayo endoscopic subscore (MES) was used to assess endoscopic disease activity. MES has been classified into four categories; 0, inactive; 1, mild (erythema, mild friability and decreased vascular pattern); 2, moderate (marked erythema, friability, erosions, and lack of vascular pattern,); and 3, severe (ulcerations and spontaneous bleeding). [17] In left-sided or pancolitis, the score was given based on the area with the most severe inflammatory segment. Two board-certified endoscopy experts (S. R. J and H. G. K), who were blinded to the clinical and laboratory information, reviewed the endoscopic images. If disagreement occurred between the two reviewers, the endoscopic activity score was determined based on the consensus of the two reviewers. Findings of FC tested in one month and endoscopy performed in three months were used. The median time interval between endoscopy and FC measurement was 1 (interquartile range [IQR] 0-14) days.

Therapeutic plan adjustment was defined as the addition or increased dosage of anti-inflammatory drugs, steroids, immunomodulators, and biologics after endoscopy following the FC test in patients with UC.

Categorical and continuous variables were compared using the chi-squared test and two-tailed Student's t-test, respectively. Correlations among FC, disease activity, and endoscopic activity were assessed using Spearman's correlation coefficient. Receiver operating characteristic (ROC) curve analysis was used to determine the appropriate time interval to assess the association between the FC test and endoscopic disease activity in patients with UC. The sensitivity, specificity, accuracy, positive predictive value (PPV), and negative predictive value (NPV) according to the time interval between FC measurement and endoscopy were assessed using ROC curve analyses. After assessing the connection between the FC test and MES, we used the Youden index method to estimate the appropriate time interval between examinations. Finally, the area under the curve (AUC) was compared for each criterion (>200 mg/g, >250 mg/g, or >300 mg/ g) using Delong's test. Statistical significance was set at p < 0.05. The Bonferroni correction method was used to solve the multiple testing problem. All statistical analyzes were performed using version 3.6.1 ("pROC" and "Optimal Cut points" packages) and SPSS 19.0 (SPSS Inc., Chicago, IL).

Eighty-six patients with UC who underwent endoscopy were initially enrolled in the study. Seven patients were excluded (five for unexamined fecal samples, one for having a concomitant gastrointestinal infection, and one for bowel resection). Finally, 79 patients with UC were enrolled in the study. The median age of patients with UC was 39 years (IQR 25-51 years), and 64.5% (51/79) were men. The median Mayo scores at the time of diagnosis and FC measurements were 6 (IQR 4-6) and 4 (IQR 2-7), respectively. The median FC level was 285.8 (77.0-749.1). The clinical characteristics of patients with UC, including laboratory tests and medications, at FC measurements are summarized in Table 1 . (Fig. 1) . Therapeutic plans were changed in 29.1% of the total enrolled patients. In patients with shorter intervals ( 7 days) between the FC test and endoscopy, more significant therapeutic plan adjustments were observed with longer intervals (>7 days) in patients with UC (36.5% vs. 17.5%, P = .047) ( Table 3 ).

This study aimed to analyze the appropriate time interval to confirm the association between the FC test and endoscopic activity in patients with UC, and to identify when to perform endoscopy for adjustment of the therapeutic plan in UC patients with high FC. To our knowledge, although all previous studies focused on FC testing only as a role for the diagnosis and clinical follow-up of inflammatory bowel disease (IBD), no study has examined the appropriate time interval to confirm the association between the FC test and endoscopic disease activity in patients with UC. In addition, this study investigated whether the therapeutic plan was changed according to the time interval between the FC test and endoscopic examination in UC patients with high FC. Although we found that the appropriate time interval for determining the association between FC and MES was 7 days in UC patients with FC 200 mg/g or more, this result did not have statistically significant implications. However, we found that endoscopy within a shorter interval ( 7 days) in UC patients with high FC (≥ 200 mg/g) can help determine the therapeutic plan.

Because an increase in the FC level during serial measurements is a marker of increased mucosal activity and may predict the clinical relapse of IBD, FC measurements are performed before initiating IBD therapy and during regular follow-up every three or six months throughout during treatment. [13, 18] When the FC level is increased, endoscopy is considered to decide whether to escalate or to keep the current treatment. According to a previous study, FC could be a useful tool to identify endoscopically active UC and be helpful to monitor disease activity and decide on treatment escalation. [19] Ideally, accurate mucosal inflammation can be evaluated by performing endoscopy on the same day as the increase in the FC level was observed. A recent guideline recommended that fecal samples not be stored for three days or more at room temperature prior to analysis. [18] In real world practice, however, FC measurement and endoscopy are often not performed on the same day because of a lack of fecal sampling, collection delays, patients' personal circumstances, or institutional practice patterns. In our study, endoscopy was performed within three days after FC measurement in 59% of cases (61/103) and at the same time after FC measurement in only 37% (38/ 103).

In a study, the authors illustrated that a 57 mg/g cutoff value for FC predicted endoscopic mucosal inflammation as defined by the modified Baron Index ≥ 2 with a specificity and sensitivity of 90% and 91%, respectively. [20] However, another study revealed Table 1 Baseline characteristics at diagnosis in patients with ulcerative colitis. that FC with a 250 mg/g cutoff level had a specificity and sensitivity of 100% and 71%, respectively, for active mucosal inflammation as defined by a MES ≥ 1. [21] Likewise, optimal cutoff values for predicting mucosal inflammation has been reported from 50-250 mg/g in UC patients due to the use of various endoscopic activity indices, type and location of the disease, and variability between different assay methods or in different fecal samples from similar patients during one day. [13, 18, 22] However, according to an expert opinion on the interpretation of cutoff values for FC in IBD patients, FC less than 100 mg/g was associated with mucosal remission. [13] In our study, although a positive value of FC was ≥ 50 mg/g, we divided the patients into active and inactive mucosal inflammations based on FC with a 100 mg/g cutoff value. This study showed that the optimal cutoff of the appropriate time interval for dividing the association and non-association between FC and MES was 7 days using an ROC curve with a cutoff level of 200 mg/g for FC. The sensitivity, specificity, accuracy, PPV, and NPV were observed to be the highest at 74.4%, 50.0%, 61.2%, 55.6%, and 70.0%, respectively, compared with the cutoff values of FC 250 or 300 mg/g. Unfortunately, this result did not show statistically significant implications, such as the high values of AUC, sensitivity, and specificity. This may be due to the small sample size and retrospective design of the single-center study with potential bias. Contrary to the study purpose, we could not make a definitive conclusion as the disease activity may be evaluated through an endoscope within 7 days in UC patients with FC scores of 200 mg/g or higher.

Many studies have reported that FC correlates better with endoscopic disease activity than serum inflammatory biomarkers. [23] [24] [25] [26] A study reported that UC patients with shorter periods ( 14 days) between the FC measurement and endoscopy, the higher correlation with endoscopic disease activity. [27] On the other hand, there was no significant correlation difference in our patients with shorter intervals ( 7 days) between the FC test and endoscopic evaluation as shown Figure 1 . Patients with longer intervals (> 7 days) showed a gradual increase in the FC level correlated with increasing MES, which was not as well captured a that in patients with shorter intervals ( 7 days). In UC patients with shorter intervals, one patient with MES 0 compared with 27 patients with MES1 showed higher FC. This may be explained by the mucosal evaluation in part of the large bowel using sigmoidoscopy, not colonoscopy was performed in only one patient with an MES of 0. Although the AUC according to the time interval ( 7 days) between the FC measurement and endoscopy was not statistically significant, more significant therapeutic plan adjustments were observed in patients with shorter intervals ( 7 days) than in longer intervals (>7 days) in patients with UC. Therefore, these results imply that endoscopy within a shorter interval can help in therapeutic decisions in patients with UC with high FC.

The limitations of our study include its retrospective, single institution with a relatively small sample size. There is much bias against changing therapeutic plans, which made it difficult to evaluate the effect of all covariates influencing therapeutic plan adjustment, due to the limitations of the retrospective analysis. To compensate for these limitations, we are planning a welldesigned prospective study to confirm the study purpose and conduct multivariable logistic regression analysis to evaluate the effect of covariates for therapeutic plan adjustment. Endoscopic activity was assessed using only MES because of the major limitation of the retrospective design. The endoscopic index of UC has been reported to be a reliable endoscopic activity index in patients with UC. [28, 29] Although MES is not validated, it is the most widely used index. [17] To evaluate endoscopic activity, and the final endoscopic score was determined after two experts independently assessed the endoscopic images and reached an agreement.

In conclusion, endoscopy within 7 days after detecting high calprotectin levels did not adequately reflect the activity of endoscopic disease severity, whereas endoscopy within a shorter Table 2 The receiver operator characteristic curve and area under the curve according to the time interval between the fecal calprotectin (FC) measurement and endoscopy for determining the association between FC and Mayo endoscopic subscore. Table 3 Therapeutic plan adjustment for patients according to the time interval after performing endoscopy in ulcerative colitis with high calprotectin.

Shorter intervals ( 7 days 

Course of ulcerative colitis: analysis of changes in disease activity over years

Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis

Epidemiological trend in inflammatory bowel disease in Taiwan from 2001 to 2015: a nationwide populationbased study

Changing epidemiological trends of inflammatory bowel disease in Asia

Mucosal healing in inflammatory bowel diseases: a systematic review

Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis

Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis

From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting

Accuracy of three different fecal calprotectin tests in the diagnosis of inflammatory bowel disease

Fecal calprotectin: a reliable predictor of mucosal healing after treatment for active ulcerative colitis

The role of platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in ulcerative colitis

Systematic review with metaanalysis: fecal calprotectin as a surrogate marker for predicting relapse in adults with ulcerative colitis

Expert opinion for use of faecal calprotectin in diagnosis and monitoring of inflammatory bowel disease in daily clinical practice

Management of inflammatory bowel disease in the COVID-19 era

Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study

British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults

Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis

Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes

Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

The intra-individual variability of faecal calprotectin: a prospective study in patients with active ulcerative colitis

Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI

The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease

C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis

Relationship of clinical symptoms with biomarkers of inflammation in pediatric inflammatory bowel disease

Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis

Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)

Reliability and initial validation of the ulcerative colitis endoscopic index of severity